Medtronic's Intellis spinal cord stimulator algorithm delivers back pain relief at one-year mark

Spine
About twice as many Intellis patients saw more than an 80% reduction in their pain scores, at 69% compared to 35% among those who received conventional spinal cord stimulation therapy. (Michael Dorausch CC BY-SA 2.0)

By employing pain treatment algorithms that vary electrical pulses based on the patient’s movement and target them to the cellular activity within their spinal cord, Medtronic has shown that its implant's programming can deliver strong, sustained pain relief for at least one year compared to conventional neurostimulation therapy.

Touted as an alternative to opioid painkillers since its 2017 approvals in the U.S. and Europe, the devicemaker’s Intellis spinal cord stimulator demonstrated it could cut reported back pain by at least half among 84% of patients in a randomized study while using the technique, compared to 51% of a group that received conventional stimulation doses from the device.

In addition, about twice as many patients given the therapy saw reductions of more than 80% in their pain scores, at 69% of those treated compared to 35%, according to the company. The pain treatment algorithm is known as Differential Target Multiplexed, or DTM therapy, which modulates the electrical signals sent to the spinal cord to help synchronize interactions between the nervous system’s neurons and glial cells.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

RELATED: Medtronic launches brain-stim programmer on a Samsung phone

The 79-person study had previously met its primary noninferiority endpoint after only three months, as Medtronic reported this past January, while the latest data showed those outcomes could be sustained out to 12 months. The company describes its miniaturized, tablet-controlled Intellis implant as the world’s smallest fully implantable spinal cord stimulator.

Medtronic picked up ownership of DTM therapy earlier this year following its work with—and eventual acquisition of—the Illinois-based developer Stimgenics. Glial cells, which DTM's frequencies specifically target, outnumber neurons in spinal cord tissue by a 12-to-1 ratio, and they are thought to play a much more active role there in the transmission of pain signals.

RELATED: Medtronic's rechargeable neurostimulator implant nets FDA approval for bladder and bowel control

The Intellis implant also automatically adjusts its stimulation based on the patient's body position, such as when they are lying down, sitting or standing up. That movement may shift the location of the spinal cord and its distance from the implant’s electrodes, requiring a stronger or milder electric pulse.

Suggested Articles

GE Healthcare has launched a new algorithm that can read X-rays and help assess the correct placement of ventilator tubes in critical patients.

Months after approving a COVID-19 shot based on early data, Russia is reporting data from nearly 19,000 people showing it is more than 90% effective.

Early-stage biotech Elevian has raised $15 million as it looks to target multiple age-related diseases.